Castle Biosciences (NASDAQ: CSTL) CEO sells 30,779 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Castle Biosciences Inc. President and CEO Derek J. Maetzold reported open-market sales of a total of 30,779 shares of common stock on March 13 and 16, 2026, at weighted-average prices of $25.447, $25.964 and $26.680 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following the sales, he holds 40,779 shares directly and also has indirect holdings through several family and grantor retained annuity trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 30,779 shares ($792,410)
Net Sell
12 txns
Insider
MAETZOLD DEREK J
Role
Pres. & Chief Exec. Officer
Sold
30,779 shs ($792K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 17,449 | $25.964 | $453K |
| Sale | Common Stock | 126 | $26.68 | $3K |
| Sale | Common Stock | 13,204 | $25.447 | $336K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 40,905 shares (Direct);
Common Stock — 51,566 shares (Indirect, By The Maetzold Descendants 2020 Trust)
Footnotes (1)
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 3, 2025. This transaction was executed in multiple trades at prices ranging from $25.210 to $25.785, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $25.660 to $26.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
FAQ
What did CSTL CEO Derek Maetzold report in this Form 4 filing?
He reported selling 30,779 shares of Castle Biosciences common stock in open-market transactions. The sales occurred on March 13 and 16, 2026 at weighted-average prices between $25.447 and $26.680 per share, as disclosed in the filing and its footnotes.
Were Derek Maetzold’s CSTL stock sales made under a Rule 10b5-1 plan?
Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025. Such plans pre-schedule trades, which can indicate these sales followed an established program rather than ad hoc market timing decisions.